Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
Elevated aldosterone causes moderate to severe increase in blood pressure, and leads to
various target organ damage including cardiovascular ones. Aldosterone has been considered
one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently,
the use of mineralocorticoid receptor antagonists(MRA) has been proven to reduce blood
pressure levels, but long-term prognostic data are lacking in hypertensive patients.
Therefore, the purpose of this clinical trial is to assess the effect of MRA on
cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.